UltraGreen ai (ULG) investor relations material

Executive summary

• Revenue grew 24% year-over-year to $87.2 million in H1 2026, with net profit up 53% to $39.2 million and underlying NPAT before exceptional items up 45% to $39.4 million, reflecting strong commercial momentum and market expansion in Europe and Asia.

• Gross margin improved to 87% from 85%, driven by favorable pricing, geographic mix, and higher ICG vial sales.

• Interim dividend of $0.01 per share declared, with a target of semi-annual dividends and share buybacks, including a buyback of approximately one million shares.

• Expanded market access in Europe and Asia, securing regulatory approvals for key products and PerfusionWorks software, with certification pending.

Financial highlights

• Gross profit increased to $75.5 million, with gross margin at 87% and operating profit at $47.5 million.

• Adjusted EBITDA up 16% to $52.5 million, with margin at 60%, and basic EPS rose 53% to 3.56 US cents.

• Net cash and short-term investments rose 12% to $197.6 million as of June 30, 2026.

• Administrative expenses rose 92% to $24.1 million, mainly due to higher headcount, IPO-related costs, and share option expenses.

Outlook and guidance

• FY2026 revenue guidance tightened to $175–185 million, with 2H2026 revenue expected to exceed 1H2026 and net margin expected to remain stable at about 45%.

• Growth in H2 expected to be volume-driven, with no major ASP increases planned.

• Double-digit growth in both revenue and underlying net profit projected for FY2026, supported by market expansion and regulatory progress.